150 related articles for article (PubMed ID: 36482811)
1. Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Goto Y
Int J Urol; 2023 Sep; 30(9):704. PubMed ID: 36482811
[No Abstract] [Full Text] [Related]
2. Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Ito K; Kita Y; Kobayashi T
Int J Urol; 2023 Sep; 30(9):696-703. PubMed ID: 36482843
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
4. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
Bellmunt J; Nadal R
Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
[TBL] [Abstract][Full Text] [Related]
5. [First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)].
Rexer H; Ohlmann CH; Retz M
Urologe A; 2017 May; 56(5):659-661. PubMed ID: 28349185
[No Abstract] [Full Text] [Related]
6. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
Parikh M; Pan CX; Beckett LA; Li Y; Robles DA; Aujla PK; Lara PN
Clin Genitourin Cancer; 2018 Dec; 16(6):421-428.e1. PubMed ID: 30166228
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
Taguchi S; Kawai T; Nakagawa T; Kume H
BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
[No Abstract] [Full Text] [Related]
8. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
Narita T; Hatakeyama S; Numakura K; Kobayashi M; Muto Y; Saito M; Narita S; Tanaka T; Noro D; Tokui N; Yoneyama T; Hashimoto Y; Habuchi T; Ohyama C
Int J Urol; 2021 Sep; 28(9):899-905. PubMed ID: 34028105
[TBL] [Abstract][Full Text] [Related]
10. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
[TBL] [Abstract][Full Text] [Related]
12. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
[No Abstract] [Full Text] [Related]
13. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zacharis A; Grüllich C
Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
[TBL] [Abstract][Full Text] [Related]
14. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
[TBL] [Abstract][Full Text] [Related]
15. NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
Gupta S; Kamat AM
Nat Rev Urol; 2020 Sep; 17(9):491-492. PubMed ID: 32632305
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
17. [Drug approval: Enfortumab vedotin-advanced urothelial carcinoma (which have previously received platinum-containing chemotherapy and immunotherapy)].
Matte P; Campedel L
Bull Cancer; 2022; 109(7-8):738-740. PubMed ID: 35606195
[No Abstract] [Full Text] [Related]
18. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
Zhu X; Koshkin VS
Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
[TBL] [Abstract][Full Text] [Related]
19. Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
Sonpavde GP; Sternberg CN; Loriot Y; Marabelle A; Lee JL; Fléchon A; Roubaud G; Pouessel D; Zagonel V; Calabro F; Banna GL; Shin SJ; Vera-Badillo FE; Powles T; Hellmis E; Miranda PAP; Lima AR; Emeribe U; Oh SM; Hotte SJ
Eur J Cancer; 2022 Mar; 163():55-65. PubMed ID: 35042068
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
Necchi A; Nishiyama H; Matsubara N; Lee JL; Petrylak DP; de Wit R; Drakaki A; Liepa AM; Mao H; Bell-McGuinn K; Powles T
BMC Urol; 2020 Nov; 20(1):181. PubMed ID: 33160359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
